Protalix Biotherapeutics Inc Cash Flow Conversion Efficiency
Protalix Biotherapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Protalix Biotherapeutics Inc (PLX) has a cash flow conversion efficiency ratio of 0.042x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.03 Million) by net assets ($48.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Protalix Biotherapeutics Inc (1996–2025)
Cash flow conversion efficiency of Protalix Biotherapeutics Inc from 1996 to 2025. This chart illustrates how Protalix Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PLX live share price for real-time trading data and today's change.
Protalix Biotherapeutics Inc Cash Flow Conversion Ratio Explained
Protalix Biotherapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Protalix Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Protalix Biotherapeutics Inc ranked by their cash flow conversion efficiency. Also see Protalix Biotherapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rugvista Group AB
ST:RUG
|
0.006x |
|
Inission AB (publ)
ST:INISS-B
|
0.058x |
|
BF Investment Limited
NSE:BFINVEST
|
0.001x |
|
Great Rich Technologies Limited
KQ:900290
|
0.036x |
|
Formuepleje Limittellus
CO:FPILIM
|
N/A |
|
Zen Voce
TWO:3581
|
-0.017x |
|
Orvana Minerals Corp.
TO:ORV
|
0.525x |
|
EDAP TMS S.A.
NASDAQ:FOCL
|
1.143x |
Annual Cash Flow Conversion Efficiency for Protalix Biotherapeutics Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Protalix Biotherapeutics Inc from 1996 to 2025. Review Protalix Biotherapeutics Inc (PLX) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $48.23 Million | $-11.99 Million | -0.249x | -223.88% |
| 2024-12-31 | $43.21 Million | $8.67 Million | 0.201x | +611.27% |
| 2023-12-31 | $33.57 Million | $-1.32 Million | -0.039x | -101.67% |
| 2022-12-31 | $-10.64 Million | $-25.00 Million | 2.350x | +37.89% |
| 2021-12-31 | $-6.04 Million | $-10.29 Million | 1.704x | +76.47% |
| 2020-12-31 | $-27.04 Million | $-26.11 Million | 0.966x | +250.76% |
| 2019-12-31 | $-70.32 Million | $-19.36 Million | 0.275x | +88.03% |
| 2018-12-31 | $-52.88 Million | $-7.74 Million | 0.146x | -54.16% |
| 2017-12-31 | $-31.29 Million | $-9.99 Million | 0.319x | -90.09% |
| 2016-12-31 | $-9.96 Million | $-32.10 Million | 3.224x | +244.34% |
| 2015-12-31 | $10.87 Million | $-24.28 Million | -2.233x | -524.10% |
| 2014-12-31 | $-55.60 Million | $-29.28 Million | 0.527x | -53.71% |
| 2013-12-31 | $-26.95 Million | $-30.65 Million | 1.138x | +701.39% |
| 2012-12-31 | $-3.36 Million | $635.00K | -0.189x | -120.93% |
| 2011-12-31 | $-26.08 Million | $-23.57 Million | 0.904x | -73.39% |
| 2010-12-31 | $-11.32 Million | $-38.46 Million | 3.397x | +21.38% |
| 2009-12-31 | $15.88 Million | $44.45 Million | 2.799x | +874.99% |
| 2008-12-31 | $44.35 Million | $-16.02 Million | -0.361x | -120.10% |
| 2007-12-31 | $63.69 Million | $-10.45 Million | -0.164x | +21.74% |
| 2006-12-31 | $24.28 Million | $-5.09 Million | -0.210x | -164.51% |
| 2005-12-31 | $914.43K | $-72.47K | -0.079x | +76.65% |
| 2004-12-31 | $495.36K | $-168.12K | -0.339x | -62.75% |
| 2003-12-31 | $655.43K | $-136.68K | -0.209x | -13.26% |
| 2002-12-31 | $796.15K | $-146.59K | -0.184x | +77.94% |
| 2001-12-31 | $945.91K | $-789.43K | -0.835x | -2011.77% |
| 2000-12-31 | $1.34 Million | $-53.11K | -0.040x | +95.54% |
| 1999-12-31 | $1.59 Million | $-1.41 Million | -0.886x | -226.92% |
| 1998-12-31 | $3.35 Million | $-909.52K | -0.271x | -- |
| 1997-12-31 | $0.00 | $-247.92K | x | -- |
| 1996-12-31 | $0.00 | $-40.57K | x | -- |
About Protalix Biotherapeutics Inc
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also d… Read more